Differential carbohydrate binding and cell surface glycosylation of human cancer cell lines

Currently there is only a modest level knowledge of the glycosylation status of immortalised cell lines that are commonly used in cancer biology as well as their binding affinities to different glycan structures. Through use of glycan and lectin microarray technology, this study has endeavoured to define the different bindings of cell surface carbohydrate structures to glycan‐binding lectins. The screening of breast cancer MDA‐MB435 cells, cervical cancer HeLa cells and colon cancer Caco‐2, HCT116 and HCT116–FM6 cells was conducted to determine their differential bindings to a variety of glycan and lectin structures printed on the array slides. An inverse relationship between the number of glycan structures recognised and the variety of cell surface glycosylation was observed. Of the cell lines tested, it was found that four bound to sialylated structures in initial screening. Secondary screening in the presence of a neuraminidase inhibitor (4‐deoxy‐4‐guanidino‐Neu5Ac2en) significantly reduced sialic acid binding. The array technology has proven to be useful in determining the glycosylation signatures of various cell‐lines as well as their glycan binding preferences. The findings of this study provide the groundwork for further investigation into the numerous glycan–lectin interactions that are exhibited by immortalised cell lines. J. Cell. Biochem. 112: 2230–2240, 2011. © 2011 Wiley‐Liss, Inc.

[1]  C. Day,et al.  Identification and characterization of the aspartate chemosensory receptor of Campylobacter jejuni , 2010, Molecular microbiology.

[2]  Z. Li,et al.  Optimal and consistent protein glycosylation in mammalian cell culture. , 2009, Glycobiology.

[3]  J. Tiralongo,et al.  Differential Carbohydrate Recognition by Campylobacter jejuni Strain 11168: Influences of Temperature and Growth Conditions , 2009, PloS one.

[4]  David F. Smith,et al.  Novel fluorescent glycan microarray strategy reveals ligands for galectins. , 2009, Chemistry & biology.

[5]  Y. Li,et al.  Lectin microarrays identify cell-specific and functionally significant cell surface glycan markers. , 2008, Glycobiology.

[6]  Keiko Hata,et al.  Limited Inhibitory Effects of Oseltamivir and Zanamivir on Human Sialidases , 2008, Antimicrobial Agents and Chemotherapy.

[7]  K. Yamaguchi,et al.  Roles of plasma membrane-associated sialidase NEU3 in human cancers. , 2008, Biochimica et biophysica acta.

[8]  Chung-Yi Wu,et al.  Glycan arrays: biological and medical applications , 2008, Current Opinion in Chemical Biology.

[9]  V. Korolik,et al.  MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. , 2007, The Journal of clinical investigation.

[10]  G. Hart,et al.  O‐GlcNAc turns twenty: functional implications for post‐translational modification of nuclear and cytosolic proteins with a sugar , 2003, FEBS letters.

[11]  J. Hirabayashi.  Oligosaccharide microarrays for glycomics. , 2003, Trends in biotechnology.

[12]  Toshihiko Oka,et al.  Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. , 2002, Biochimica et biophysica acta.

[13]  S. Hakomori,et al.  Glycosylation defining cancer malignancy: New wine in an old bottle , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  K. Yamaguchi,et al.  Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Christian A. Rees,et al.  Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.

[16]  J. Dennis,et al.  Glycoprotein glycosylation and cancer progression. , 1999, Biochimica et biophysica acta.

[17]  R Apweiler,et al.  On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. , 1999, Biochimica et biophysica acta.

[18]  S. Gendler,et al.  The epithelial mucin, MUC1, of milk, mammary gland and other tissues. , 1995, Biochimica et biophysica acta.

[19]  K. Breen,et al.  The control of sialyltransferase activity in tumor‐cell lines derived from different tissues is multifactorial , 1995, FEBS letters.

[20]  R. Iozzo,et al.  Altered proteoglycan gene expression and the tumor stroma , 1993, Experientia.

[21]  C. Jumarie,et al.  Caco‐2 cells cultured in serum‐free medium as a model for the study of enterocytic differentiation in vitro , 1991, Journal of cellular physiology.

[22]  B. Toole.  Hyaluronan and its binding proteins, the hyaladherins. , 1990, Current opinion in cell biology.

[23]  J. Dennis,et al.  Tumor cell surface beta 1-4-linked galactose binds to lectin(s) on microvascular endothelial cells and contributes to organ colonization , 1990, The Journal of cell biology.

[24]  G. Schapira,et al.  Alterations in glycosylation of plasma membrane proteins during myogenesis. , 1983, Experimental cell research.

[25]  J. Dennis,et al.  Surface sialic acid reduces attachment of metastatic tumour cells to collagen type IV and fibronectin , 1982, Nature.

[26]  M. Brattain,et al.  Heterogeneity of malignant cells from a human colonic carcinoma. , 1981, Cancer research.

[27]  M. Olivé,et al.  Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization , 1978, In Vitro.

[28]  P. Harper,et al.  George Otto Gey. (1899-1970). The HeLa cell and a reappraisal of its origin. , 1971, Obstetrics and gynecology.

[29]  E. S. Stevens,et al.  Glycosaminoglycans: structure and interaction. , 1980, CRC critical reviews in biochemistry.